ABSTRACT :- 2-Deoxy-D-Glucose (2-Deoxyglucose, 2-DG) is a glucose analogue that inhibits glycolysis via its actions on hexokinase, the rate limiting step of glycolysis. It is phosphorylated by hexokinase to 2-DG-P which cannot be further metabolized by phosphoglucose isomerase. It is non-metabolizable glucose analogue. Inhibits phosphorylation of glucose by hexokinase; causes depletion of cellular ATP. Also inhibits phosphoglucose isomerase (PGI) competitively. Causes cell cycle inhibition and cell death in in vitro models of hypoxia; blocks tumour cell growth in animal models. Also shown to induce the unfolded protein response (UPR). The ability of 2-deoxy-D-glucose (2-DG) to interfere with D-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress cancer cell growth and survival. In addition to glycolysis inhibition, other molecular processes are also affected by 2-DG. Attempts to improve 2-DG’s drug-like properties, its role as a potential adjuvant for other chemotherapeutics, and novel 2-DG analogues as promising new anti-cancer agents, as anti-covid drug and used to treat some neurogenerative disorders. This present critical review reported the applications of 2-DG.This understanding, at least in part, explains the profound effects that the analogue of glucose, 2-deoxy-D-glucose, has been shown to have on as common and widespread diseases as cancer, viral infection, aging-related morbidity, epilepsy, and others.